Ovarian Cancer Drugs Market Size, Share & Growth Report 2031

Report Description

Ovarian Cancer Drugs Market Outlook 2031

The Global Ovarian Cancer Drugs Market size was valued at USD 3.37 Billion in 2022 and is likely reach to USD 5.99 Billion by 2031, expanding at a CAGR of 6.6% during the forecast period, 2023–2031. The growth of the market is attributed to the rising prevalence of ovarian cancer due to an aging population and bad lifestyles.

The ovaries are two reproductive glands in females that generate ova, or eggs. They also make estrogen and progesterone, which are feminine hormones. When abnormal cells in the ovary begin to proliferate out of control and form a tumor, this is referred to as ovarian cancer. The tumor might spread to other regions of the body if it is not treated.

Metastatic ovarian cancer is the term for this type of malignancy. Warning indications of ovarian cancer are common, although the early symptoms are frequently vague and easy to dismiss. Ovarian cancer is identified at an early stage in 20% of cases. Ovarian cancer's specific cause is undetermined.

A family history of ovarian cancer, genetic abnormalities in ovarian cancer genes such as BRCA1 or BRCA2, a personal history of breast, uterine, or colon cancer, obesity, the use of certain fertility medications or hormone treatments, no history of pregnancy, and endometriosis can all raise patient’s risk.

Three types of cells make up the ovaries. Each cell has the potential to become a distinct form of tumor. Epithelial cancers develop in the outer layer of tissue of the ovaries. Epithelial tumors make up around 90% of ovarian malignancies. Stromal cancers develop in the cells that produce hormones.

Stromal tumors make up 7% of all ovarian malignancies. Germ cell cancers form in the cells that produce eggs. Germ cell cancers are extremely uncommon.

Get Free Sample Report

When doctor identifies ovarian cancer early on, it is significantly simpler to treat. It is, however, difficult to identify. The following tests may also be performed by the doctor. Transvaginal ultrasound (TVUS), CT scans of the abdomen and pelvis, blood tests to determine cancer antigen 125 (CA-125) levels, biopsies, and laparoscopies are all tests’ options for diagnosis.

It is crucial to remember that, while all of these tests can assist doctor in making a diagnosis, only a biopsy can confirm whether or not patients have ovarian cancer. The therapy is determined on the extent of the cancer's spread. Depending on your circumstances, a team of specialists will devise a treatment plan.

Chemotherapy, surgery to stage the disease and remove the tumor, targeted therapy, and hormone therapy are all likely to be part of the treatment plan. There are no established methods for completely removing your risk of ovarian cancer. There are, however, actions you may do to reduce your risk.

Taking oral birth control pills, nursing, pregnancy, and surgical operations on your reproductive organs have all been proven to reduce your chance of getting ovarian cancer (like a tubal ligation or hysterectomy). The most prevalent form of ovarian cancer is epithelial ovarian cancer.

Survival rates may vary depending on the kind of ovarian cancer, how far the disease has progressed, and how far therapies have progressed. Scientists are actively working on more refined and reliable methods of early detection of ovarian cancer. Treatment progresses, and with it, the prognosis for ovarian cancer improves.

Several Phase II and III clinical studies examining checkpoint inhibitors in combo regimens are under underway. Unmet needs in the ovarian cancer medication market offer a great potential to develop ground-breaking first-in-class treatments. The introduction of non-platinum-based PARP inhibitors and VEGF inhibitors in second and third-line ovarian cancer treatment is radically altering the therapeutic paradigm.

Companies are increasingly concentrating their efforts on the development of targeted medicines as innovative ovarian cancer treatment regimens. With many first-in-class breakthroughs, the future treatment market is likely to gain an assortment of novel targets and therapy types, extending the breadth of possible advantages for patients.

Market Trends, Drivers, Restraints, and Opportunities

• Increasing prevalence ovarian cancer projected to boost the market growth during the forecast period.
• Growing geriatric population and adoption of unhealthy lifestyle are key factors driving the market growth during the forecast period.
• Increased acceptance of new medicines and the availability of a robust development pipeline are estimated to propel the market growth during the forecast period.
• Increasing use of checkpoint inhibitors anticipated to spur the market growth in the coming years.
• Increased usage of biologics and targeted therapies are projected to hamper the market growth during the forecast period.
• Lack of accurate diagnostic techniques in early stages of ovarian cancer is anticipated to hinder the market growth during the forecast period.
• Increased R&D investments for novel development of drug and treatments for effective treatment and diagnosis and technological advancements are projected to create lucrative opportunities for the market players.

Scope of Ovarian Cancer Drugs Market Report

The report on the global ovarian cancer drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Ovarian Cancer Drugs Market Segment Insights

PARP inhibitors and angiogenesis inhibitors segment is expected to account for a key share

Based on therapeutic class, the ovarian cancer drugs market is segmented into PARP inhibitors, angiogenesis inhibitors, and PD-L1 inhibitors. The PARP inhibitors and angiogenesis inhibitors segment is expected to account for a key share of the market during the forecast period owing to its increasing use.

Both Zejula and Rubraca, PARP inhibitors, have showed promising outcomes in early trials and compete directly with AstraZeneca's Lynparza.

The utilization of new therapies such as immunotherapy, targeted therapy, and, most critically, combination regimens is the focus of current ovarian cancer research. Immuno-oncologic drugs have showed encouraging outcomes in terms of increased lifespan and reduced toxicity.

However, the single-agent response rate of PD-1/PD-L1 drugs like Opdivo and Keytruda for the treatment of ovarian cancer is less than 20%.

Combination treatments, particularly those that include checkpoint inhibitors, are poised to be launched in the first-line context to address significant unmet requirements such as tumor resistance, progression-free survival, and quality of life.

Get Free Sample Report

Ovarian Cancer Drugs Market Regional Outlook

North America is anticipated to dominate the market

On the basis of regions, the ovarian cancer drugs market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market during the forecast period.

The regional market growth can be attributed to new product releases, higher acceptance of innovative treatments, a large target population, and a rise in the incidence of ovarian cancer.

On the other hand, Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing to increasing prevalence of ovarian cancer, positive healthcare reforms, growing health awareness, low-cost base, and absence of regulatory and cultural inhibitions in countries such as India and China.

Get Free Sample Report